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Summary.-Neitherradiationalone(375to 1500rad)nor5-fluorouracil (FU)alone(50-
250 mg/kg) is sufficient to prevent an increase in the volume of the solid tumour
model hepatoma 3924A. However, as little as 750 rad with 100 mg/kg FU can
reduce the tumour below the volume at the time of treatment for as long as 14 days.
A series of combined FU and radiation doses given every 11 days should then result
in successively smaller tumour volumes until the tumour is eradicated.
Changes in tumour volume were analysed by two different methods: (1) tumours
in each treatment mode were grouped together and the average response to treat-
ment determined, and (2) tumour volume changes in individual tumours were
analyzed utilizing the x2 technique, which fits the logarithmic tumour volume
change with time to polynomials. This two-directional method of analysis has the
advantage of permitting both an overview of the main effects of treatment via the
averages, and at the same time a detailed examination of the mechanism by which
these effects occur through the analysis of individual responses.
The results suggest that, in addition to concentrating on the cellular response
immediately after therapy, greater emphasis should be placed on the kinetic changes
of the tumour 1-3 weeks after single or multiple modality therapy. These findings
demonstrate how the sequencing of single and/or combined treatment modalities
may be investigated in order to determine how best to obtain maximum effects of
treatment on different types of tumours following recovery of the host from the
previous treatment series.
THERE is increasing evidence that human
neoplasms are more responsive to combi-
nation therapy (Bleehen, 1973; DeVita,
Young and Canellos, 1975; Doggett and
Bagshaw, 1974; Mavligit et al., 1975;
Rosenberg and Kaplan, 1975; Vongtama et
al., 1975). One ofthe more promising areas
for improving the clinical management
of solid tumours is the proper sequence
ofone or more treatment modalities.
A synergistic effect has been noted
with the drug 5-fluorouracil (FU) if it is
given 20 h before or 10 h after radiation,
using a spleen colony assay (Vietti,
Eggerding and Valeriote, 1971). These
observations have not been thoroughly
evaluated in experimental solid tumours.
However, one possible explanation for this
synergistic effect is that the first agent
produces a partial synchrony, increasing
the number of cells in the more sensitive
stages of the cell cycle when the second
agent is given. Results from studies with
the solid tumour model hepatoma 3924A
have shown that there is a two-to-three-
fold increase in tumour-cell synchrony
following radiation or FU, with the maxi-
mum increase occurring 12 h after single
exposure to radiation and 24 h after FU
in this solid tumour (Kovacs et al., 1975,
1976a).
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to radiation alone, FU alone, and FU
given 12 h after local tumour irradiation
in this solid tumour model has been made.
Theresultshavebeenanalysedbycompari-
son of the changes in mean tumour
volumes of the different groups of treated
tumours. The effects on the tumour of
combining FU and radiation treatment
were shown by analysis of variance to be
additive at, certain times and probably
more than additive at other times. In
addition, individual tumour responses
have been investigated by computer
fitting of growth curves and studying the
percentage of tumours exhibiting 3 types
ofresponse as a function ofFU and radia-
tion. A comparison of these 2 treatment
modalities has uncovered specific re-
sponses to radiation and FU which were
masked in the analysis using only mean
tumour volumes as the evaluating index.
The results indicate that a series of
combined FU and radiation doses given at
11-day intervals should in principle result
in progressively smaller tumour volumes
until the tumour is eradicated (Looney
et al., 1976a; Hopkins et at., 1976; Kovacs
et al., 1975, 1976a; Kovacs, Evans and
Wakefield, 1976b). This therapeutic pro-
tocol now being tested would essentially
transform the situation from an untreat-
able to a treatable one as neither the
radiation dose alone (375-1500 rad) nor
the FU dose alone (50-120 mg/kg) controls
tumour growth.
MATERIALS AMD METHODS
Solid tumour line 3924A.-Hepatoma
3924A was induced originally in an ACI
female rat by feeding N-2 fluorenyldiaceta-
mide, and is maintained in this host by
transplantation at monthly intervals (Morris,
1975). It is a fast-growing, poorly differen-
tiated tumour. The parenchymal tumour
cells are hypotetraploid, having 73 chromo-
somes, 10ofwhich areabnormal. Thetumour
contains at least two populations of cells, one
having a modal DNA content similar to that
of diploid mammalian cells and the other
having a DNA content corresponding to that
of tetraploid tumour cells. The kinetics of
cell proliferation and tumour growth are as
follows. The actual volume doubling time
for 3924A is 96-3 h; the potential volume
doubling time is 42 h. The cell cycle time
is 27-4 h. The different phases of the cycle
are as follows: G1-14 h, S-9-3 h, G2
3.7 h and M-0{4 h. The 1-h thymidine
labelling index was 17-6. The growth factor
was 066 and the cell loss factor 061 (Looney
et al., 1971, 1973, 1976b).
The tissue composition remained constant
at 51% tumour, 18% necrotic, 26% connec-
tive, and5% blood, fortumours with volumes
ranging from 70 to 350 mm3. Over a range
of tumour size (0'2-12-0 g) the relative cell
density of 3924A remains constant, 95% of
the cells being of parenchymal tumour type,
with the remainder being associated with the
connective tissue and vascular framework of
the hepatoma (Kovacs et al., 1975, 1976a).
One of the major advantages of this
tumour line is that it rarely metastasizes.
This permits studies with the primary which
are related to the effects of treatment on
the tumour, without the deleterious effects
of metastases on the host. Wepsic, Nickel,
and Alaimo (1976) have demonstrated that
3924A has tumour-specific antigens. There-
fore, the failure of the tumour to metastasize
mayberelated tothe antigenic responseofthe
host to the tumour.
Radiation.-Local tumour radiation was
carried out with a 250 kV, 30 mA General
Electric Maxitron 250 X-ray machine using
filters of 025 mm Cu and 1-0 mm Al. Prior
to irradiation, the animals were anaesthetized
with ether and placed in a lead-shielded box
through which the tumour protruded. The
midpoint of the tumour was approximately
6 cm from the X-ray tube target and received
the calculated dose, while the animal body
received 0-5% of the dose delivered to the
irradiated tumour. A plexiglass cover was
placed over the animal and the target cone
lowered to prevent tumour displacement.
5-Fluorouracil (FU).-FU (Roche Labora-
tories, Hoffman-La Roche Inc., Nutley, New
York) prepared in sterile saline was given by
i.p. injection between 8.00 and 8.30 a.m.
Control animals were injected with saline.
Tumour volume measurements.-Tumour
volumes (mm3) were calculated (1 I x w x h)
from measurements of length, width and
height made daily for 2-4 days before treat-
ment and 1-2 weeks after treatment, and
during the period ofmajor changes in tumour
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growth rates. Variability of growth rates of
individual tumours determined by this
method decreased considerably after indivi-
dual tumours had reached a minimum of
200 mm3. For this reason, experiments were
scheduled when animals could be grouped
with a mean tumour volume of 200 mm3 or
larger (Looney et al., 1973).
X-ray experiment.-The rats in the radia-
tion studies were divided into 9 groups of
16 rats each. One group of 16 rats acted as
control and the other 6 groups were given
375, 750, 1500, 2250, 3000 and 3750 rad of
radiation locally to the tumour.
FU experiment.-The rats in the FU
studies were divided into 6 groups of 12 rats
each. One group of 12 animals acted as
control and the other 5 groups were given
a single injection of 50, 100, 150, 200 and
250 mg/kg.
Combined X-ray and FU experiment.-
Three different doses of X-rays and 3 different
doses of FU were given, to determine the
relationship between these two different
treatment modalities. The FU was given
12 h after local tumour irradiation, to take
advantage of the partial synchronization of
the cells by local tumour irradiation at this
time (Kovacs et al., 1976a).
Female ACI/c rats, injected with 3924A
hepatoma, were randomly selected for this
3 x 3 drug (FU) vs X-ray study. Each
group contained 11 rats. Local tumour
irradiation was followed by FU 12 h post-
radiation.
X-ray dose
FU mg/kg
50
100
150
375 rad
A
B
C
750 rad
D
E
F
1500 rad
G
H
I
Controls: J: 1500 rad and saline
K: Anaesthetic and 150 mg/kg FU
L: Anaesthetic and saline
RESULTS
The results of this experiment have
been analysed in 2 different ways. First,
the tumours in each treatment mode were
grouped together and the average response
to treatment determined. The analysis
shows that, on the average, the combined
therapy prolonged the period during
which the tumour was maintained
at a small volume. Secondly, techniques
described elsewhere (Looney et al., 1976a)
were used to analyse the response ofindivi-
dual tumours to the combined treatment.
Fig. 1 shows the average relative
volume for a number oftreatment groups.
The average volumes of each group have
been divided by the average volume at
treatment (V0) for the group. The re-
sponse to 150 mg/kg FU shows, on the
DAYS AFTER TREATMENT
FIG. 1.-Average volume response to single
and combined treatments. Each curve is
average of approximately 11 animals; the
volumes have been divided byV0, the aver-
age volume at treatment at each dose. The
single error bars are + 1 standard error of
the mean; the double error bars are ± 1
standard deviation.
average, that the tumour is growing
steadily except between Days 4 and 10,
where it is constant at approximately
2-5 V0. For the 1500-rad dose, the aver-
age volume continues to increase from
Day 0 to 2 V0 at Day 3. Then it re-
gresses to 1-5 V0, and eventually regrows
to 2 V0 atDay 11. The combined modality
curve (1500 rad + 150 mg/kg) is essen-
tially parallel to the 1500-rad curve, but
lower by a factor of approximately 2/3.
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The results indicated that, at the 90%
confidence level, the combined treatment
effect is simply additive at 8 days (when
the volume reduction is maximal). There
is some evidence for a marginally signifi-
cant synergistic effect at 16 days. How-
ever, the difference between 1500 rad
alone and 1500 rad plus FU is not great
at this point.
The maximum effects on the average
tumour volume change for either FU
alone or X-rays alone or a combination
of FU and X-rays occurs approximately
8 days after treatment (Fig. 1). The
average tumour volumes on Day 8
following treatment are 30, 15 and 10%
ofthe mean control volumes for FU alone,
X-rays alone, and FU plus X-rays respec-
tively.
The basis ofthe second type ofanalysis
DAYS AFTER TREATMENT
FIG. 2. The response of individual animals
to various treatments: (a) control; (b)
150 mg/kg of FU; (c) 1500 rad; (d) 1500
rad + 100 mg/kg FU. The solid curves
are the polynomial fits to the logarithm of
(V/V0). The error bars are + 1 standard
deviation in volume measurement at that
particular volume.
has been discussed in detail elsewhere
(Looney et al., 1976a), but the essential
feature is that a smooth curve represent-
ing a polynomial fit to ln (V/V0) can be
obtained, which fits an individual
tumour's response very well within experi-
mental error. The data in Fig. 2 are
representative of both the raw data and
the fitted functions. By analysing each
tumour response individually within a
treatment group, non-uniform responses
can be accommodated and volumes can
be more accurately known for analysis.
Once each individual growth curve in
a treatment group has been fitted, the
response can be separated into 3 classes:
Class I, regression; Class II, pseudo-
regression; and Class III, slow-down.
Having performed this classification the
simplest characterization of a particular
treatment is the tabulation of the percen-
tage oftumours which fall into each class.
Fig. 3 shows dose-response histograms
(DRH) for 50, 100 and 150 mg/kg of FU
as a function of radiation dose. The
radiation dose scale has been repeated
3 times at each FU dose, in order to show
the histograms of each class separately.
A number of important points emerge
from the histogram for the combined
treatments:
(1) FU used in combination with
X-ray lowers the X-ray dose at
which some tumours begin to
exhibit regression;
(2) The addition ofFUgreatlyreduces
the number of tumours which
show no tolume reduction at all,
and seems to move significant
numbers oftumours from Class III
to Class II responses at X-ray
levels above 500 rad.
(3) Thepercentageoftumoursexhibit-
ing regression (Class I) at the
highest X-ray doses used does not
seem to be sensitive to FU, but
remains roughly constant.
The analysis of individual tumour
responses shows that the effect of com-
bining FU with X-rays is to lower the
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FIG. 3.-Dose response histogram for combined therapy. The radiation axis has been repeated to
show each class separately.
threshold at which regression occurs, and
to increase the incidence of pseudo-
regression at the expense of slow-down
responses. It does not appear to increase
the delay time for those tumours which
would exhibit regression from the X-ray
treatment alone. The increase in delay
time seen in the average responses does
not result from an increase in the delay
time for those tumours which are already
showing regression, but rather from an
increased response from the relatively
insensitive tumours.
Table I lists for the Class I-B response
to 1500 rad, the delay times (TD) and
the quantity defined by:
Vmin
'Vmax
where Vmax is the maximum volume
attained immediately after treatment,
TABLE I.-Delay Time (TD) and Efficiency
(v) at 1500 rad for Class I-B* (Definite
Regression)
FU dose TD 1
0 18±3 0-50±0-14
100 17±7 0 45±0 40
150 13_-3 0-32+0-02
*FU doses not listed have too few responses in
this class for meaningful results.
and Vmin is the minimum volume after
treatment. Figure 4a shows a graphical
interpretation ofTD and P. The quantity
y may be termed the " treatment effi-
ciency ". There is no discernible trend
for either delay time or treatment effi-
ciency to increase with increasing doses
of FU within statistical errors, as Table I
indicates. Class II has both a Vmax
and Vmin: however, the volume never
regresses below the treatment volume.
The quantity, y', can be defined as above,
258SYNERGISM OF X-RAYS AND FLUOROURACIL
LL
D V.
0
D V.
0
(a)
Vmax
Vmin V
- TD
to
TIME
(b)
Vma x
I -- mi
___ __1
to
TIME
FIG. 4.-Delay time definitions for (a) definite-
local regression (Class I-B), and for (b)
pseudo-local regression (Class II).
TABLE II.-DelayTime (TD') andEfficiency
(y') for Class 11* (Pseudo-Local Regres-
sion)
FU dose
150
50
100
150
TD' 71
7±1 0-15±0-13
7±2 0-12±0-04
6±1 0-07±0 03
6±1 0-05±0-02
* FU doses not listed have too few responses
in this class for meaningful results.
and the delay time, TD', is modified
to be the time it takes a pseudo-regressing
tumour to regain volume prior to regres-
sion. Figure 4b shows the graphical
interpretation of TD' and y', and Table II
again shows no FU dose dependence.
DISCUSSION
Previous studies by Denekamp (1974),
Denekamp and Thomlinson (1971), Her-
mens and Barendsen (1975), Suit, Shalek
and Wette (1965), and Thomlinson and
Craddock (1967), and prior reports of this
series (Looney et al., 1975, 1976a) have
shown that much useful information can
be obtained by analysis of changes in the
average tumour volumes following radia-
tion. Some of these studies have also
demonstrated the advantages of using
computer-derived growth curves which
are simulated from the volumes of the
individual tumoursratherthantheaverage
tumour volume at any specific time after
treatment. The ability to generate data
from a family of growth curves permits a
more precise evaluation of the effects of
different treatment modalities on experi-
mental solid tumours.
Treatmentof3924Aproducesmaximum
tumour volume change 12 days after FU
and 20 days after X-rays (Looney et al.,
1976a). These times for maximum
tumour volume change for both radiation
and FU are largely independent of dose,
although they have not been determined
for other tumours with different growth
rates. The temporal difference for maxi-
mum rate of tumour volume change
following combined FU and X-ray therapy
becomes apparent when the individual
tumour growth curves are examined
(Fig. 2). Following X-rays, the tumour
volume curve remains flat for a longer
period of time than following FU treat-
ment, where essentially no flatness occurs.
Instead, there is a gradual increase in the
tumourvolume, even duringthe first week
after treatment. The response to com-
bined FU and X-ray therapy is similar
to that after radiation alone.
It is evident from the results of FU
and X-rays on 3924A, that times equiva-
lent to several cell cyclesandactualvolume
doubling times transpire before the tumour
recovers enough to grow at rates equal
to or greater than controls. More infor-
mation will be needed to assess accurately
the relationship between the immediate
effects of treatment on tumour cell viabil-
ity and the eventual manifestation of the
effects on the tumour as evidenced by
maximum tumour volume changes 1-3
weeks after treatment.
Schabel (1974) has pointed out that
"the presumption that experimental
tumours which have been serially trans-
planted for many years in inbred hosts are
X-ray
dose
375 rad
750 rad
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uniformly responsive to treatment with
effective drugs is demonstrably invalid.
Therefore, experimental cancer chemo-
therapists should change their classical
procedures for analysis of drug response
of tumours to those commonly used in
clinical medicine ". Schabel's observa-
tions of variation in therapeutic response
in experimental tumours have been con-
firmed in our studies on solid tumours
investigated to date. Thus, a systematic
and quantitative method of analysis
using individual tumour volume changes
as an end-point is more closely related to
the method for clinical evaluation. The
dose response histogram (DRH) in Fig. 3,
which plots the percentage of tumours
exhibiting a particular mode of response
as afunction ofdose,represents anattempt
to systematically examine experimental
data obtained from one such end-point
which can be evaluated clinically.
More data points with large groups of
animals would provide a continuous
spectrum of changes within the 3 classes
of response. Suit et al. (1965) has given
a readily definable experimental end-point
for the tumour regression (Class I) for
radiation: the TDC50 dose is the dose
which would be expected on the average
to result in tumour regression in one half
ofthe tumours irradiated. The treatment
whichwillproducepseudo-regression (Class
II) or slow-down (Class III) in 50% of
the tumours could also be determined,
providing a readily definable biological
end-point for all 3 classes of response.
This provides the means for quantitative
evaluation and comparison of changes in
tumour response following multiple moda-
lity therapy.
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